A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery

Sergio D. Bergese, Timothy I. Melson, Keith A Candiotti, Sabry S. Ayad, Randall J. Mack, Stewart W. McCallum, Wei Du, Alexis Gomez, Jorge E. Marcet

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

An intravenous (IV) formulation of meloxicam is being studied for moderate to severe pain management. This phase 3, randomized, multicenter, double-blind, placebo-controlled trial evaluated the safety of once-daily meloxicam IV 30 mg in subjects following major elective surgery. Eligible subjects were randomized (3:1) to receive meloxicam IV 30 mg or placebo administered once daily. Safety was evaluated via adverse events, clinical laboratory tests, vital signs, wound healing, and opioid consumption. The incidence of adverse events was similar between meloxicam IV– and placebo-treated subjects (63.0% versus 65.0%). Investigators assessed most adverse events as mild or moderate in intensity and unrelated to treatment. Adverse events of interest (injection-site reactions, bleeding, cardiovascular, hepatic, renal, thrombotic, and wound-healing events) were similar between groups. Over the treatment period, meloxicam IV was associated with a 23.6% (P =.0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects. The results suggest that meloxicam IV had a safety profile similar to that of placebo with respect to numbers and frequencies of adverse events and reduced opioid consumption in subjects with moderate to severe postoperative pain following major elective surgery.

Original languageEnglish (US)
JournalClinical Pharmacology in Drug Development
DOIs
StatePublished - Jan 1 2019

Fingerprint

meloxicam
Placebos
Safety
Opioid Analgesics
Wound Healing
Vital Signs
Pain Management
Postoperative Pain
Morphine
Research Personnel
Hemorrhage

Keywords

  • meloxicam
  • nonsteroidal anti-inflammatory drug
  • postoperative pain
  • safety
  • surgery

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery. / Bergese, Sergio D.; Melson, Timothy I.; Candiotti, Keith A; Ayad, Sabry S.; Mack, Randall J.; McCallum, Stewart W.; Du, Wei; Gomez, Alexis; Marcet, Jorge E.

In: Clinical Pharmacology in Drug Development, 01.01.2019.

Research output: Contribution to journalArticle

Bergese, Sergio D. ; Melson, Timothy I. ; Candiotti, Keith A ; Ayad, Sabry S. ; Mack, Randall J. ; McCallum, Stewart W. ; Du, Wei ; Gomez, Alexis ; Marcet, Jorge E. / A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery. In: Clinical Pharmacology in Drug Development. 2019.
@article{e18341f505bc4d358cf875894444002d,
title = "A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery",
abstract = "An intravenous (IV) formulation of meloxicam is being studied for moderate to severe pain management. This phase 3, randomized, multicenter, double-blind, placebo-controlled trial evaluated the safety of once-daily meloxicam IV 30 mg in subjects following major elective surgery. Eligible subjects were randomized (3:1) to receive meloxicam IV 30 mg or placebo administered once daily. Safety was evaluated via adverse events, clinical laboratory tests, vital signs, wound healing, and opioid consumption. The incidence of adverse events was similar between meloxicam IV– and placebo-treated subjects (63.0{\%} versus 65.0{\%}). Investigators assessed most adverse events as mild or moderate in intensity and unrelated to treatment. Adverse events of interest (injection-site reactions, bleeding, cardiovascular, hepatic, renal, thrombotic, and wound-healing events) were similar between groups. Over the treatment period, meloxicam IV was associated with a 23.6{\%} (P =.0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects. The results suggest that meloxicam IV had a safety profile similar to that of placebo with respect to numbers and frequencies of adverse events and reduced opioid consumption in subjects with moderate to severe postoperative pain following major elective surgery.",
keywords = "meloxicam, nonsteroidal anti-inflammatory drug, postoperative pain, safety, surgery",
author = "Bergese, {Sergio D.} and Melson, {Timothy I.} and Candiotti, {Keith A} and Ayad, {Sabry S.} and Mack, {Randall J.} and McCallum, {Stewart W.} and Wei Du and Alexis Gomez and Marcet, {Jorge E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cpdd.666",
language = "English (US)",
journal = "Clinical Pharmacology in Drug Development",
issn = "2160-763X",
publisher = "Sage Periodicals Press",

}

TY - JOUR

T1 - A Phase 3, Randomized, Placebo-Controlled Evaluation of the Safety of Intravenous Meloxicam Following Major Surgery

AU - Bergese, Sergio D.

AU - Melson, Timothy I.

AU - Candiotti, Keith A

AU - Ayad, Sabry S.

AU - Mack, Randall J.

AU - McCallum, Stewart W.

AU - Du, Wei

AU - Gomez, Alexis

AU - Marcet, Jorge E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - An intravenous (IV) formulation of meloxicam is being studied for moderate to severe pain management. This phase 3, randomized, multicenter, double-blind, placebo-controlled trial evaluated the safety of once-daily meloxicam IV 30 mg in subjects following major elective surgery. Eligible subjects were randomized (3:1) to receive meloxicam IV 30 mg or placebo administered once daily. Safety was evaluated via adverse events, clinical laboratory tests, vital signs, wound healing, and opioid consumption. The incidence of adverse events was similar between meloxicam IV– and placebo-treated subjects (63.0% versus 65.0%). Investigators assessed most adverse events as mild or moderate in intensity and unrelated to treatment. Adverse events of interest (injection-site reactions, bleeding, cardiovascular, hepatic, renal, thrombotic, and wound-healing events) were similar between groups. Over the treatment period, meloxicam IV was associated with a 23.6% (P =.0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects. The results suggest that meloxicam IV had a safety profile similar to that of placebo with respect to numbers and frequencies of adverse events and reduced opioid consumption in subjects with moderate to severe postoperative pain following major elective surgery.

AB - An intravenous (IV) formulation of meloxicam is being studied for moderate to severe pain management. This phase 3, randomized, multicenter, double-blind, placebo-controlled trial evaluated the safety of once-daily meloxicam IV 30 mg in subjects following major elective surgery. Eligible subjects were randomized (3:1) to receive meloxicam IV 30 mg or placebo administered once daily. Safety was evaluated via adverse events, clinical laboratory tests, vital signs, wound healing, and opioid consumption. The incidence of adverse events was similar between meloxicam IV– and placebo-treated subjects (63.0% versus 65.0%). Investigators assessed most adverse events as mild or moderate in intensity and unrelated to treatment. Adverse events of interest (injection-site reactions, bleeding, cardiovascular, hepatic, renal, thrombotic, and wound-healing events) were similar between groups. Over the treatment period, meloxicam IV was associated with a 23.6% (P =.0531) reduction in total opioid use (9.2 mg morphine equivalent) compared to placebo-treated subjects. The results suggest that meloxicam IV had a safety profile similar to that of placebo with respect to numbers and frequencies of adverse events and reduced opioid consumption in subjects with moderate to severe postoperative pain following major elective surgery.

KW - meloxicam

KW - nonsteroidal anti-inflammatory drug

KW - postoperative pain

KW - safety

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85061929558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061929558&partnerID=8YFLogxK

U2 - 10.1002/cpdd.666

DO - 10.1002/cpdd.666

M3 - Article

C2 - 30786162

AN - SCOPUS:85061929558

JO - Clinical Pharmacology in Drug Development

JF - Clinical Pharmacology in Drug Development

SN - 2160-763X

ER -